CAR-T, bispecifics or ADCs in late-stage RRMM
CAR-T, bispecifics or ADCs in late-stage RRMM
Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma